Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) filed its Monthly Return for Equity Issuer covering the period ended 31 October 2026, showing a stable capital structure with no new share issuances, cancellations, or treasury share activity.
Authorised and Issued Share Capital • Authorised ordinary H-share capital remained at 78.71 million shares with a par value of RMB 1.00 each, equivalent to authorised capital of RMB 78.71 million. • Issued share capital was unchanged at 78.71 million shares; no shares were held in treasury. • Consequently, total issued shares at month-end stood at 78.71 million, identical to the previous month.
Public Float Compliance Haixi Pharma confirmed compliance with the Main Board’s minimum public float threshold of 25 % of issued H shares as of 31 October 2026.
Capital Instruments The company reported no outstanding share options, warrants, convertible securities, depositary receipts or other arrangements that could dilute existing shareholders.
Governance The filing was submitted by Joint Company Secretary Mr. Zhang Junhuan on 2 November 2026, in accordance with Hong Kong Stock Exchange requirements.
Comments